Company: PTHS
Filing Date: 2025-05-27
Form Type: DEFM14C
Source: 0001140361-25-020509
Chunk: 414

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-27
Form: DEFM14C
Chunk 414
---
 approving and reviewing executive officer and director compensation arrangements, plans, policies and programs; |

| • | administering our cash-based and equity-based compensation plans; and |

| • | making recommendations to the combined company’s board of directors regarding any other board of director responsibilities relating to executive compensation. |

Nominating and Corporate Governance Committee Following the completion of the Merger, the members of the combined company’s nominating and corporate governance committee are expected to be Messrs. Baxter and Pauls, each of whom qualifies as an independent director, as defined under applicable The NYSE American listing rules. Mr. Pauls is expected to chair the nominating and corporate governance committee.

235

TABLE OF CONTENTS

The combined company’s nominating and corporate governance committee will be responsible for, among other things:

| • | identifying, considering and recommending candidates for membership on the combined company’s board of directors; |

| • | overseeing the process of evaluating the performance of the combined company’s board of directors; and |

| • | advising the combined company’s board of directors on other corporate governance matters. |

Code of Business Conduct and Ethics Following the completion of the Merger, the combined company will adopt a written code of business conduct and ethics that will apply to all of the combined company’s directors, officers and employees, including the combined company’s principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. The code of business conduct and ethics will cover fundamental ethics and compliance-related principles and practices such as accurate accounting records and financial reporting, avoiding conflicts of interest, the protection and use of the combined company’s property and information, reporting of illegal or unethical behavior, competition and fair dealing and compliance with legal and regulatory requirements. Following the completion of the Merger, a current copy of the combined company’s code of business conduct and ethics will be posted on the investor relations section of the combined company’s website. If the combined company makes any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, the combined company will disclose the nature of such amendment or waiver on the combined company website or in a Current Report on Form 8-K. Compensation Committee Interlocks and Insider Participation In connection with the closing of the Merger, the combined company’s board of directors is expected to select members of the compensation committee. Each member of the compensation committee is expected to be a “non-employee” director within the meaning of Rule 16b-3 of the rules promulgated